Trade-Ideas LLC identified

Inogen

(

INGN

) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Inogen as such a stock due to the following factors:

  • INGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $17.0 million.
  • INGN has traded 63,851 shares today.
  • INGN is up 3.1% today.
  • INGN was down 10.5% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in INGN with the Ticky from Trade-Ideas. See the FREE profile for INGN NOW at Trade-Ideas

More details on INGN:

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. INGN has a PE ratio of 87. Currently there are 5 analysts that rate Inogen a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Inogen has been 314,900 shares per day over the past 30 days. Inogen has a market cap of $768.6 million and is part of the health care sector and health services industry. Shares are up 11.6% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Inogen as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

Highlights from the ratings report include:

  • INGN's revenue growth has slightly outpaced the industry average of 37.8%. Since the same quarter one year prior, revenues rose by 38.7%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • INGN's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 4.25, which clearly demonstrates the ability to cover short-term cash needs.
  • INOGEN INC has improved earnings per share by 18.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, INOGEN INC reported lower earnings of $0.34 versus $1.22 in the prior year. This year, the market expects an improvement in earnings ($0.46 versus $0.34).
  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 69.83% over the past year, a rise that has exceeded that of the S&P 500 Index. Looking ahead, however, we cannot assume that the stock's past performance is going to drive future results. Quite to the contrary, its sharp appreciation over the last year is one of the factors that should prompt investors to seek better opportunities elsewhere.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. When compared to other companies in the Health Care Equipment & Supplies industry and the overall market, INOGEN INC's return on equity is below that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.